Tilray Inc. ($TLRY) Stock Forecast: Down 6.6% Today

What is Tilray Inc.?

Tilray Brands, Inc. (T.TLRY) operates in the pharmaceutical distribution industry, with a significant presence in the medical cannabis sector. Despite recent accolades for innovation and operational excellence, the stock encountered notable bearish movement in the market today.

Why is Tilray Inc. going down?

TLRY stock is down 6.6% on Feb 5, 2026 16:18

• The acknowledgment of Tilray Pharma's CC Pharma as a TOP 100 Innovator in Germany underlines the company's dedication to innovation and operational excellence within the pharmaceutical distribution industry.
• Notwithstanding this positive development, the decrease in Tilray Brands shares could be linked to profit-taking by investors following a recent uptrend or broader market uncertainties impacting the stock price.
• The forthcoming nationwide promotional campaign in Tilray's U.S. craft beer taprooms might have shifted investor attention away from the pharmaceutical sector, resulting in a temporary decline in the stock price.
• Investors may be anticipating the upcoming financial update in early April to evaluate the company's overall performance and growth trajectory, possibly influencing the bearish sentiment surrounding the stock today.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands, Inc.

Tilray Brands, Inc.'s Tilray Pharma arm announced that its European distribution business, CC Pharma, has been recognized as a TOP 100 Innovator in Germany. This prestigious award acknowledges CC Pharma's innovation among small and mid-sized enterprises. Despite this positive news, Tilray Brands shares (T.TLRY) were trading down by $1.12 at $10.49.

http://www.baystreet.ca/articles/stocksinplayarticles.aspx?id=46447

Stocks in play: Tilray Brands, Inc.

Tilray Brands, Inc. announced that its Tilray Pharma arm's European distribution business, CC Pharma, has been recognized as a TOP 100 Innovator in Germany. Despite this recognition, Tilray Brands shares are currently trading down $1.12 at $10.49. The article highlights other market data and analytical information relevant to Canadian investors.

https://www.theglobeandmail.com/investing/markets/stocks/TLRY-T/pressreleases/23520/stocks-in-play-tilray-brands-inc/

CC Pharma Recognized as a TOP 100 Innovator in Germany by Tilray Brands, Inc.

Tilray Pharma's CC Pharma has been recognized as a TOP 100 Innovator in Germany for its significant contributions to the pharmaceutical distribution industry. The company, which serves over 13,000 pharmacies nationwide and is a key distributor of medical cannabis, received the accolade for its exceptional innovation management, sustainable competitiveness, and commitment to operational excellence. Both the International President of Tilray Brands and CC Pharma's Managing Director highlighted the importance of this recognition in validating the company's forward-thinking approach and strategic positioning for future growth.

https://www.quiverquant.com/news/CC+Pharma+Recognized+as+a+TOP+100+Innovator+in+Germany+by+Tilray+Brands%2C+Inc.

Tilray’s CC Pharma Recognized as a TOP 100 Innovator in Germany

Tilray Pharma's European distribution business, CC Pharma, has been named a TOP 100 Innovator in Germany, a prestigious recognition for innovation among small and mid-sized enterprises. This award highlights CC Pharma's role as a trusted partner in the European pharmaceutical market, providing reliable access to medicines and playing a key part in medical cannabis distribution in Germany. The recognition underscores CC Pharma's commitment to innovation, operational excellence, and its contribution to Germany's healthcare supply chain.

https://finance.yahoo.com/news/tilray-cc-pharma-recognized-top-120000663.html

Tilray Leverages Craft Beer Portfolio for Major US Sports Weekend

Tilray Brands is launching a nationwide promotional campaign across its U.S. craft beer taprooms, timed for a major U.S. sporting event on February 8. The campaign, which includes discounted beer packages and food-and-beverage bundles, follows Tilray's Q2 fiscal 2026 financial report revealing record net revenue of $218 million. Concurrently, Tilray continues to expand its European medical cannabis operations and plans to release its next financial update in early April.

https://www.ad-hoc-news.de/boerse/news/ueberblick/tilray-leverages-craft-beer-portfolio-for-major-us-sports-weekend/68550165

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 13.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 11.4% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 11.3% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 5.0% Today

Chewy Inc ($CHWY) Stock Forecast: Up 5.1% Today

International Paper Company ($IP) Stock Forecast: Up 5.8% Today

Coupang LLC ($CPNG) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 5.0% Today

Tilray Inc. Price History

29.00.2026 - TLRY Stock was down 7.2%

• Tilray's stock plummeted by 3.6% recently due to various reasons:
• Analyst downgrades and missing earnings per share (EPS) figures in the most recent report raised concerns among investors, leading to a decline in stock value.
• The stock's movement below its 50-day and 200-day moving averages signifies a pessimistic market sentiment.
• Despite positive updates about expanding its European medical cannabis platform in Italy, the company encounters obstacles like regulatory challenges, competition from multi-state operators, and high short interest, contributing to its overall underwhelming performance.
• Although the announcement of the SweetWater 420 Fest by Tilray's branch, SweetWater Brewing Company, was positive for the brand, it did not notably impact the stock's trajectory.
• Various analysts' price targets and ratings, for instance, Canaccord Genuity Group's hold rating and a price target of C$13.00, depict a cautious outlook on Tilray's stock performance in the near future.
• Investors keenly observe developments regarding the potential reclassification of U.S. medical cannabis and the company's efficacy in managing losses to evaluate future stock performance amidst previous declines and dilution risks.

13.00.2026 - TLRY Stock was down 5.3%

• Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
• The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
• Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
• Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

22.00.2026 - TLRY Stock was up 5.1%

• TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
• The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
• Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
• The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

05.01.2026 - TLRY Stock was down 6.6%

• The acknowledgment of Tilray Pharma's CC Pharma as a TOP 100 Innovator in Germany underlines the company's dedication to innovation and operational excellence within the pharmaceutical distribution industry.
• Notwithstanding this positive development, the decrease in Tilray Brands shares could be linked to profit-taking by investors following a recent uptrend or broader market uncertainties impacting the stock price.
• The forthcoming nationwide promotional campaign in Tilray's U.S. craft beer taprooms might have shifted investor attention away from the pharmaceutical sector, resulting in a temporary decline in the stock price.
• Investors may be anticipating the upcoming financial update in early April to evaluate the company's overall performance and growth trajectory, possibly influencing the bearish sentiment surrounding the stock today.

12.00.2026 - TLRY Stock was up 4.9%

• Reported a record Q2 Fiscal 2026 net revenue of $218 million, led by strong performance in international cannabis and Canadian adult-use cannabis segments.
• Transitioned to a net cash position and reaffirmed full-year Adjusted EBITDA guidance, highlighting disciplined execution and a strengthened balance sheet.
• Analysts' opinion that the recent share plunge was overdone aligns with financial results, suggesting potential undervaluation due to underestimation of profit growth in Canadian and international cannabis markets.
• Strategic expansion into the beverage segment, along with readiness to leverage medical cannabis infrastructure in the U.S., positions the company for future growth amidst potential regulatory shifts in the cannabis market.

28.00.2026 - TLRY Stock was down 5.2%

• Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
• Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
• The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
• The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

16.00.2026 - TLRY Stock was down 5.1%

• Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
• The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
• Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
• Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

• Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
• Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
• The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
• Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

06.00.2026 - TLRY Stock was down 5.2%

• The bearish movement in Tilray's stock today can be attributed to multiple factors:
• The formation of a bearish head-and-shoulders pattern, indicating a potential trend reversal and investor caution.
• Heightened volatility ahead of the earnings release, with analysts expecting significant price swings and a projected loss per share.
• The company's expansion into non-alcoholic, cannabis-infused beverages for its "Dry January" campaign might not have been well-received by investors, impacting the stock negatively.
• Investors are closely monitoring Tilray's financial results release on January 9th, potential cannabis reclassification efforts in the US, and the impact of increased competition in the US market for further insights into the stock's performance.

02.00.2026 - TLRY Stock was up 5.6%

• Tilray's stock is struggling to maintain momentum despite recent U.S. regulatory shifts and political support, trading below key technical levels.
• Investor focus is on the upcoming Q2 earnings report, with expectations of a loss per share on revenue. Analysts are looking for signs of financial progress from cost-saving measures and brand integrations.
• The stock's increased attention on social media platforms is sparking discussions about whether TLRY's current mid-single digit trading price reflects a genuine recovery or speculative hype.
• Analysts have a cautiously optimistic stance, considering potential U.S. policy changes and growth in Tilray's alcohol business, balanced against risks like weak cannabis sales and ongoing losses.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock price decreased by 4.2%, closing at $10.085, which was below the broader market performance.
• Analysts have given a consensus "Hold" rating with an average price target of $20, showing caution among investors.
• The drop in stock price may be linked to lower-than-expected performance and uncertainties about the upcoming second fiscal quarter results.
• Despite optimistic prospects for potential cannabis rescheduling and hemp-derived products, investors might be hesitant due to recent underperformance and competition in the AI sector.

29.11.2025 - TLRY Stock was down 5.0%

• Tilray's stock experienced a 4.2% decline in value during mid-day trading, closing at $10.085.
• Analysts have assigned a consensus "Hold" rating to Tilray, with a median price target of $20, indicating a potential upside of 88.49%.
• The bearish movement could be attributed to the cautious sentiment among analysts, despite potential positive developments such as cannabis rescheduling and revised product definitions.
• The upcoming announcement of Tilray's second fiscal quarter results may also be contributing to investor uncertainty and selling pressure on the stock.